AU2020228047B2 - Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents - Google Patents

Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents

Info

Publication number
AU2020228047B2
AU2020228047B2 AU2020228047A AU2020228047A AU2020228047B2 AU 2020228047 B2 AU2020228047 B2 AU 2020228047B2 AU 2020228047 A AU2020228047 A AU 2020228047A AU 2020228047 A AU2020228047 A AU 2020228047A AU 2020228047 B2 AU2020228047 B2 AU 2020228047B2
Authority
AU
Australia
Prior art keywords
optionally substituted
clpp
compound
onc201
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020228047A
Other languages
English (en)
Other versions
AU2020228047A1 (en
Inventor
Edwin Iwanowicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Madera Therapeutics LLC
Original Assignee
Madera Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Madera Therapeutics LLC filed Critical Madera Therapeutics LLC
Publication of AU2020228047A1 publication Critical patent/AU2020228047A1/en
Application granted granted Critical
Publication of AU2020228047B2 publication Critical patent/AU2020228047B2/en
Priority to AU2026201069A priority Critical patent/AU2026201069A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020228047A 2019-02-27 2020-02-26 Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents Active AU2020228047B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2026201069A AU2026201069A1 (en) 2019-02-27 2026-02-13 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US201962811432P 2019-02-27 2019-02-27
US62/811,432 2019-02-27
US201962819204P 2019-03-15 2019-03-15
US62/819,204 2019-03-15
US201962825667P 2019-03-28 2019-03-28
US62/825,667 2019-03-28
US201962840254P 2019-04-29 2019-04-29
US62/840,254 2019-04-29
US201962871694P 2019-07-08 2019-07-08
US62/871,694 2019-07-08
US201962885055P 2019-08-09 2019-08-09
US62/885,055 2019-08-09
US201962901142P 2019-09-16 2019-09-16
US62/901,142 2019-09-16
US201962931043P 2019-11-05 2019-11-05
US62/931,043 2019-11-05
US202062975088P 2020-02-11 2020-02-11
US62/975,088 2020-02-11
PCT/US2020/019944 WO2020176654A1 (en) 2019-02-27 2020-02-26 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2026201069A Division AU2026201069A1 (en) 2019-02-27 2026-02-13 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Publications (2)

Publication Number Publication Date
AU2020228047A1 AU2020228047A1 (en) 2021-09-30
AU2020228047B2 true AU2020228047B2 (en) 2025-11-20

Family

ID=72238693

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2020228047A Active AU2020228047B2 (en) 2019-02-27 2020-02-26 Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
AU2026201069A Pending AU2026201069A1 (en) 2019-02-27 2026-02-13 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2026201069A Pending AU2026201069A1 (en) 2019-02-27 2026-02-13 Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Country Status (7)

Country Link
US (1) US12459945B2 (enExample)
EP (1) EP3930714A4 (enExample)
JP (1) JP7709379B2 (enExample)
CN (2) CN113795251B (enExample)
AU (2) AU2020228047B2 (enExample)
CA (1) CA3131740A1 (enExample)
WO (1) WO2020176654A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
CN117580578A (zh) * 2021-05-13 2024-02-20 奇默里克斯公司 用于复发性原发性cns肿瘤的方法及用途
CN115611896A (zh) * 2021-07-16 2023-01-17 中国药科大学 含四氢萘啶酮或四氢吡啶并嘧啶酮骨架的化合物及其制备方法与制药用途
CN119997956A (zh) * 2022-08-05 2025-05-13 奇默里克斯公司 药物组合物及其用于治疗胶质瘤的用途
CN118724903A (zh) * 2023-03-31 2024-10-01 苏州安赛隆医药科技有限公司 并环结构化合物、其制备方法及其用途以及药物组合物及其用途
CN119039287A (zh) * 2023-05-29 2024-11-29 中国药科大学 一类四氢吡啶并嘧啶酮衍生物及其制备方法与应用
EP4488279A1 (en) * 2023-07-03 2025-01-08 Centro Atlantico del Medicamento S.A (Ceamed, S.A) Substituted hexahydro-2h-pyrazino[1,2-a]pyrazin-1(6h)-one derivatives as activators of human caseinolytic protease p (hsclpp)
CN121816351A (zh) * 2023-07-10 2026-04-07 苏州安赛隆医药科技有限公司 人源酪蛋白水解蛋白酶p激动剂及其用途
CN119306718A (zh) * 2023-07-11 2025-01-14 中科中山药物创新研究院 一种咪唑并吡啶并嘧啶酮类化合物及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113487A1 (en) * 2007-04-20 2010-05-06 Craig D Boyle Pyrimidinone derivatives and methods of use thereof
WO2018031987A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
WO2018031990A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
GB8810400D0 (en) 1988-05-03 1988-06-08 Southern E Analysing polynucleotide sequences
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5547839A (en) 1989-06-07 1996-08-20 Affymax Technologies N.V. Sequencing of surface immobilized polymers utilizing microflourescence detection
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
EP0430881A3 (en) 1989-11-29 1991-10-23 Ciba-Geigy Ag Photochromic compounds, process for their preparation and their use
US5288644A (en) 1990-04-04 1994-02-22 The Rockefeller University Instrument and method for the sequencing of genome
US5324633A (en) 1991-11-22 1994-06-28 Affymax Technologies N.V. Method and apparatus for measuring binding affinity
JP2775346B2 (ja) 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
US5503980A (en) 1992-11-06 1996-04-02 Trustees Of Boston University Positional sequencing by hybridization
ES2134284T3 (es) 1993-04-23 1999-10-01 Hoechst Ag Pirido-pirimidindionas, procedimiento para su preparacion y su empleo como medicamentos.
US5858659A (en) 1995-11-29 1999-01-12 Affymetrix, Inc. Polymorphism detection
US5470710A (en) 1993-10-22 1995-11-28 University Of Utah Automated hybridization/imaging device for fluorescent multiplex DNA sequencing
GB9401833D0 (en) 1994-02-01 1994-03-30 Isis Innovation Method for discovering ligands
WO1997027317A1 (en) 1996-01-23 1997-07-31 Affymetrix, Inc. Nucleic acid analysis techniques
GB9507238D0 (en) 1995-04-07 1995-05-31 Isis Innovation Detecting dna sequence variations
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5661028A (en) 1995-09-29 1997-08-26 Lockheed Martin Energy Systems, Inc. Large scale DNA microsequencing device
AU2010216633A1 (en) * 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
WO2012079164A1 (en) 2010-12-16 2012-06-21 The Governing Council Of The University Of Toronto Activators of cylindrical proteases
HUE069651T2 (hu) 2014-03-31 2025-03-28 Scripps Research Inst Farmakofór TRAIL indukcióra
CN104860948B (zh) 2015-05-15 2017-09-26 南京盖特医药技术有限公司 咪唑并嘧啶酮类化合物及其制备方法和应用
WO2020172485A1 (en) * 2019-02-22 2020-08-27 Board Of Regents, The University Of Texas System Methods of using imipridones
US20230339947A1 (en) * 2019-02-27 2023-10-26 Madera Therapeutics, LLC Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100113487A1 (en) * 2007-04-20 2010-05-06 Craig D Boyle Pyrimidinone derivatives and methods of use thereof
WO2018031987A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators
WO2018031990A1 (en) * 2016-08-12 2018-02-15 Nanjing Gator Meditech Company, Ltd. Protein kinase regulators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CAS RN 1349629-23-7; STN Entry Date 6 December 2011; 3-[(3-Fluorophenyl)methyl]-5,6,7,8-tetrahydro-6-(2-methoxybenzoyl)-2-methylpyrido[4,3-d]pyrimidin-4(3H)-one *
CAS RN 2118932-37-7 ; STN Entry Date 23 August 2017; 5,6,7,8-Tetrahydro-2-methyl-3-[(4-methylphenyl)methyl]-6-(phenylmethyl)pyrido[4,3-d]pyrimidin-4(3H)-one *
CAS RN 2121092-64-4 ; STN Entry Date 28 August 2017; 5,6,7,8-Tetrahydro-2-methyl-3-[(2-methylphenyl)methyl]-6-(phenylmethyl)pyrido[4,3-d]pyrimidin-4(3H)-one *

Also Published As

Publication number Publication date
US20220089596A1 (en) 2022-03-24
AU2020228047A1 (en) 2021-09-30
CN121758447A (zh) 2026-03-31
JP7709379B2 (ja) 2025-07-16
EP3930714A1 (en) 2022-01-05
CN113795251A (zh) 2021-12-14
WO2020176654A8 (en) 2020-10-08
EP3930714A4 (en) 2022-10-26
WO2020176654A1 (en) 2020-09-03
AU2026201069A1 (en) 2026-03-12
US12459945B2 (en) 2025-11-04
CN113795251B (zh) 2026-01-13
CA3131740A1 (en) 2020-09-03
JP2022521797A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
US12459945B2 (en) Use of caseinolytic protease P function as a biomarker of drug response to imipridone-like agents
US11472791B2 (en) Pyrazolyl pyrimidinylamine compounds as CDK2 inhibitors
US11447494B2 (en) Tricyclic amine compounds as CDK2 inhibitors
CN110392678B (zh) 用于ido和tdo调节的化合物和方法，以及其适应症
CN108883112B (zh) 用于癌症患者分级和癌症治疗的化合物、组合物和方法
DK2576510T3 (en) Piperidinonderivater as mdm2 inhibitors for cancer treatment
TW201837045A (zh) 胺基-三唑并吡啶化合物及其在治療癌症中之用途
EP3496724B1 (en) Protein kinase regulators
CN107849050B (zh) 化合物
US20240043458A1 (en) Cot modulators and methods of use thereof
KR20160090890A (ko) 친전자성 작용기를 갖는 헤테로아릴 피리돈 및 아자-피리돈 화합물
US12410152B2 (en) Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
US20230339947A1 (en) Use of caseinolytic protease p function as a biomarker of drug response to imipridone-like agents
CA3194868A1 (en) Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
EP4612154A1 (en) Regulators of porphyrin and intermediates
JP2020526495A (ja) ヘテロクロマチン遺伝子抑制阻害薬
WO2025151850A9 (en) Spirocycle acrylamides that stereo- and site-selectively degrade the transcriptional and dna-damage response protein ercc3
WO2025076470A1 (en) Sox10 inhibitors and uses thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)